Document 1015
 DOCN  M9541015
 TI    Perinatal transmission of HIV type 1: associations with maternal
       anti-HIV serological reactivity. Mothers and Infants Cohort Study and
       the HIV-1 Perinatal Serology Working Group.
 DT    9504
 AU    Goedert JJ; Dublin S; Viral Epidemiology Branch, National Cancer
       Institute, Rockville,; Maryland 20852.
 SO    AIDS Res Hum Retroviruses. 1994 Sep;10(9):1125-34. Unique Identifier :
       AIDSLINE MED/95127295
 AB    As a hypothesis-generating study of large regions of the human
       immunodeficiency virus type 1 (HIV-1) envelope, we collaborated with
       several laboratories to test sera from subgroups of 65 HIV-1-positive
       pregnant women, 18 (28%) of whom transmitted the virus to their infants.
       Assays included neutralizing antibodies to HIVLAI and reactivity to 102
       HIV-1 Env peptides with sequences based on strains LAI, MN, SC, RF, and
       WMJ-2 as well as several clinical isolates, spanning about 65% of gp120
       and about 80% of gp41. Results for the V3 loop and for neutralizing
       activity were conflicting and for the most part did not reach
       statistical significance. Transmission risk appeared lower with
       reactivity to a few gp41 epitopes (amino acids 571-585, 736-750, and
       perhaps 650-663), whereas risk appeared higher with reactivity to two
       gp120 epitopes (amino acids 466-480 and 475-486) and one gp41 epitope
       (amino acids 547-576). However, these associations could have occurred
       simply by chance because such a large number of peptides was tested.
       With independently synthesized peptides, results between laboratories
       often were inconsistent. However, reproducibility was good (rank
       correlation coefficient > or = 0.78) when the same protocols and
       peptides were used. Although this study could not identify a humoral
       immune response to linear Env peptides that consistently and broadly
       protected against perinatal transmission of HIV-1, there were regions of
       gp120 and gp41 that should be evaluated in larger cohorts and with
       techniques to investigate potential conformational epitopes and
       neutralization to autologous or clinical isolates of HIV-1 from the
       community.
 DE    Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/*TRANSMISSION  Antigenic
       Determinants/ANALYSIS  Cohort Studies  *Disease Transmission, Vertical
       Female  Gene Products, env/IMMUNOLOGY  Human  HIV Antibodies/*BLOOD  HIV
       Envelope Protein gp120/IMMUNOLOGY  HIV Envelope Protein gp41/IMMUNOLOGY
       *HIV-1/ISOLATION & PURIF  Infant, Newborn  Laboratories/STANDARDS
       Pregnancy  Pregnancy Complications, Infectious/*VIROLOGY  Prospective
       Studies  Reference Values  Reproducibility of Results  Risk Factors
       Support, U.S. Gov't, P.H.S.  CLINICAL TRIAL  CONTROLLED CLINICAL TRIAL
       JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).